All deals
You are viewing a shared deal. With a free account you access the full showcase and talk directly with whoever manages the deal.
Med-tech in digital twins for cardiovascular surgery
Capital Raising Live

Med-tech in digital twins for cardiovascular surgery

Seed
Round stage
Italy
Italy
Startup
SeedRound stage
AnyMinimum ticket
LiveStatus

Who they are & what they do

SectorHealthcare
Company overview

Builds Digital Twin software that supports cardiovascular surgeons in the diagnosis, prognosis and treatment planning of aortic aneurysms — a condition affecting roughly 700,000 people in Europe and causing around 6,000 deaths per year in Italy alone. The platform combines medical imaging, AI-based image segmentation and high-fidelity numerical simulation to reproduce a patient's biomechanical and hemodynamic response to a vascular prosthesis before surgery.

Unlike existing tools, software runs on embedded systems rather than requiring cloud computation, preserving data privacy while giving surgeons a preoperative sizing and positioning tool that — according to the company — has no direct market equivalent. Spun out of the EU-funded Horizon 2020 "MeDiTATe" project, the company won the LifeScience & MedTech category of Italy's National Innovation Award (PNICube) in 2023 and is now extending its technology to surgical planning through the EU "PANDORA" project with academic partners in Rennes and Lyon.

Key clients & traction

Cardiovascular surgeonsVascular graft manufacturersHospitals, surgical centersMedtech device makers
Company type Startup
Founded / established 2024
Country Italy

Website: Confidential

Why look at this deal

Highlights

  1. 01No cloud dependency
  2. 02PNICube award winner
  3. 03EU Horizon 2020 origin
  4. 04No direct competitor
  5. 05PANDORA project partner

Deal snapshot

Round stageSeed
InstrumentEquity
Minimum ticketAny
Pre-money valuation Confidential
Equity offeringConfidential
Revenue LTM50k

Locked fields are disclosed after expressing interest.

Data room

Public files are open to everyone. The rest unlock once you qualify.

For companies and advisors

Have a deal to bring to market?

Publish your deal on UCapital Dealflow and reach qualified buyers and investors. Data room, NDA and lead management included.

Disclaimer

UCapital Asset Management LLP is authorised and regulated by the Financial Conduct Authority (FCA) in the United Kingdom and by CONSOB in Italy, and operates in the United States through FINRA-licensed US partners and affiliates.

This platform serves informational and technological purposes only: it executes no market transactions, does not constitute a solicitation to invest and provides no financial advice of any kind. The platform lets users manage a deal through the technological tools made available to them, such as the CRM for lead tracking and analytics. No capital raising and no sale is executed on or through the platform: each individual deal is executed offline by the designated regulated entities, in accordance with the regulations in force in each country, their compliance frameworks and under their full responsibility.

The content is intended exclusively for eligible counterparties, professional investors and professional clients as defined by applicable regulations, and does not constitute a public offer. The information is not directed at persons in jurisdictions where its distribution or use would be contrary to local laws or regulations.

The data shown on these pages is public data or data collected and processed by UCapital. For user-created deals, the data is entered by the users themselves, who take full responsibility for what is published: the publication of a deal on the platform does not constitute a recommendation, endorsement or verification by UCapital.

The data shown may not always be real-time and may differ from what is verified in due diligence when contacting the regulated entities responsible for managing the deal. Any prices, valuations and projections are purely indicative.

Every investment carries risks, including the total loss of the capital invested. Past performance is not indicative of future results. Before any decision, investors must carry out their own assessments and consult the regulated entities managing the deal and, where appropriate, their own legal, tax and financial advisers.